{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:49:30Z","timestamp":1762145370802,"version":"3.40.5"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.canlet.2018.05.045","type":"journal-article","created":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T17:31:13Z","timestamp":1528133473000},"page":"69-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Precision medicine approaches may be the future for CRLF2 rearranged Down Syndrome Acute Lymphoblastic Leukaemia patients"],"prefix":"10.1016","volume":"432","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8990-2574","authenticated-orcid":false,"given":"Elyse C.","family":"Page","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan L.","family":"Heatley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul Q.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah L.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2018.05.045_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26411","article-title":"Acute lymphoblastic leukemia in patients with Down syndrome with a previous history of acute myeloid leukemia","volume":"64","author":"Tomizawa","year":"2017","journal-title":"Pediatr. Blood Canc."},{"key":"10.1016\/j.canlet.2018.05.045_bib2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/bjh.12348","article-title":"Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome","volume":"162","author":"Meyr","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2018.05.045_bib3","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bjh.13096","article-title":"Haematopoietic development and leukaemia in Down syndrome","volume":"167","author":"Roberts","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2018.05.045_bib4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2013-07-453480","article-title":"How I treat ALL in Down's syndrome: pathobiology and management","volume":"123","author":"Izraeli","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2018.05.045_bib5","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2013-06-509463","article-title":"Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group","volume":"123","author":"Buitenkamp","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2018.05.045_bib6","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1182\/blood-2007-09-114231","article-title":"Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study","volume":"111","author":"Forestier","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2018.05.045_bib7","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1182\/blood-2012-03-415448","article-title":"Targeting JAK1\/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia","volume":"120","author":"Maude","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2018.05.045_bib8","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1365-2141.2006.06337.x","article-title":"Down syndrome and acute lymphoblastic leukaemia","volume":"135","author":"Whitlock","year":"2006","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2018.05.045_bib9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/cncr.23587","article-title":"I.A.o.P.H.a.O. (AIEOP), Acute lymphoblastic leukemia and Down syndrome: presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP)","volume":"113","author":"Arico","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2018.05.045_bib10","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3324\/haematol.2009.019778","article-title":"Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia","volume":"95","author":"Buitenkamp","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2018.05.045_bib11","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s11845-014-1212-2","article-title":"Child and adolescent Down syndrome-associated leukaemia: the Irish experience","volume":"184","author":"O'Rafferty","year":"2015","journal-title":"Ir. J. Med. Sci."},{"key":"10.1016\/j.canlet.2018.05.045_bib12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1586\/ehm.10.14","article-title":"Unique clinical and biological features of leukemia in Down syndrome children","volume":"3","author":"Xavier","year":"2010","journal-title":"Expet Rev. Hematol."},{"key":"10.1016\/j.canlet.2018.05.045_bib13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/pbc.21737","article-title":"Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with Down syndrome","volume":"52","author":"Shah","year":"2009","journal-title":"Pediatr. Blood Canc."},{"key":"10.1016\/j.canlet.2018.05.045_bib14","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/leu.2011.128","article-title":"Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles","volume":"25","author":"Loudin","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2018.05.045_bib15","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ng.469","article-title":"Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia","volume":"41","author":"Mullighan","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2018.05.045_bib16","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1038\/ncomms5654","article-title":"Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations","volume":"5","author":"Nikolaev","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2018.05.045_bib17","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/ng.2949","article-title":"Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation","volume":"46","author":"Lane","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2018.05.045_bib18","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/leu.2016.164","article-title":"The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome","volume":"30","author":"Lee","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2018.05.045_bib19","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/leu.2015.113","article-title":"The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia","volume":"29","author":"Eswaran","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2018.05.045_bib20","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/gcc.22439","article-title":"Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia","volume":"56","author":"Russell","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.canlet.2018.05.045_bib21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.canlet.2017.08.034","article-title":"Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions","volume":"408","author":"Sadras","year":"2017","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2018.05.045_bib22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2162-3619-3-16","article-title":"Childhood B-acute lymphoblastic leukemia: a genetic update","volume":"3","author":"Woo","year":"2014","journal-title":"Exp. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.canlet.2018.05.045_bib23","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/leu.2016.365","article-title":"Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia","volume":"31","author":"Vesely","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2018.05.045_bib24","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood-2009-08-235408","article-title":"Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group","volume":"115","author":"Hertzberg","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2018.05.045_bib25","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1182\/blood-2015-02-580043","article-title":"Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine","volume":"125","author":"Hunger","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2018.05.045_bib26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3324\/haematol.2013.098442","article-title":"Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy","volume":"99","author":"Bibi","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2018.05.045_bib27","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2018.05.045_bib28","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1182\/blood-2009-03-208397","article-title":"Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia","volume":"114","author":"Russell","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2018.05.045_bib29","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1073\/pnas.0911726107","article-title":"Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia","volume":"107","author":"Yoda","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2018.05.045_bib30","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.1073\/pnas.0811761106","article-title":"JAK mutations in high-risk childhood acute lymphoblastic leukemia","volume":"106","author":"Mullighan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2018.05.045_bib31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia","volume":"22","author":"Roberts","year":"2012","journal-title":"Canc. Cell"},{"key":"10.1016\/j.canlet.2018.05.045_bib32","doi-asserted-by":"crossref","first-page":"E4030","DOI":"10.1073\/pnas.1702489114","article-title":"Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome","volume":"114","author":"Schwartzman","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2018.05.045_bib33","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/gcc.20451","article-title":"Specific extra chromosomes occur in a modal number dependent pattern in pediatric acute lymphoblastic leukemia","volume":"46","author":"Heerema","year":"2007","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.canlet.2018.05.045_bib34","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nrclinonc.2015.38","article-title":"Genomics in acute lymphoblastic leukaemia: insights and treatment implications","volume":"12","author":"Roberts","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2018.05.045_bib35","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1002\/cncr.29573","article-title":"Childhood acute lymphoblastic leukemia: integrating genomics into therapy","volume":"121","author":"Tasian","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2018.05.045_bib36","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrg.2016.154","article-title":"Down syndrome and the complexity of genome dosage imbalance","volume":"18","author":"Antonarakis","year":"2017","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.canlet.2018.05.045_bib37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood-2017-04-742288","article-title":"JAK2 inhibitors for myeloproliferative neoplasms: what is next?","volume":"130","author":"Bose","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2018.05.045_bib38","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/leu.2017.43","article-title":"Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile janus kinase inhibition","volume":"31","author":"Leroy","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2018.05.045_bib39","doi-asserted-by":"crossref","first-page":"89923","DOI":"10.18632\/oncotarget.21027","article-title":"Aberrations in childhood B-cell precursor acute lymphoblastic leukemia","volume":"8","author":"Steeghs","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2018.05.045_bib40","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood-2016-05-707653","article-title":"Potent efficacy of combined PI3K\/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia","volume":"129","author":"Tasian","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2018.05.045_bib41","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood-2014-06-580480","article-title":"Efficacy of JAK\/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2018.05.045_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26328","article-title":"Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia","volume":"64","author":"Mayfield","year":"2017","journal-title":"Pediatr. Blood Canc."},{"key":"10.1016\/j.canlet.2018.05.045_bib43","doi-asserted-by":"crossref","first-page":"14538","DOI":"10.1038\/srep14538","article-title":"Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance","volume":"5","author":"Kesarwani","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2018.05.045_bib44","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2011-12-389932","article-title":"Aberrant STAT5 and PI3K\/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia","volume":"120","author":"Tasian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2018.05.045_bib45","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/leu.2013.226","article-title":"Targeting the PI3K\/Akt\/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential","volume":"28","author":"Neri","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2018.05.045_bib46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.canlet.2014.02.009","article-title":"Towards precision medicine in childhood leukemia\u2013insights from mutationally activated cytokine receptor pathways in acute lymphoblastic leukemia","volume":"352","author":"Izraeli","year":"2014","journal-title":"Canc. Lett."},{"issue":"11","key":"10.1016\/j.canlet.2018.05.045_bib47","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1038\/leu.2017.93","article-title":"The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL","volume":"31","author":"Savino","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2018.05.045_bib48","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjh.14474","article-title":"Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics","volume":"176","author":"Tasian","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2018.05.045_bib49","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1172\/JCI60455","article-title":"Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome","volume":"122","author":"Malinge","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2018.05.045_bib50","article-title":"NFATc1 phosphorylation by DYRK1A increases its protein stability","volume":"12","author":"Liu","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2018.05.045_bib51","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1084\/jem.20150002","article-title":"DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3","volume":"212","author":"Thompson","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2018.05.045_bib52","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nature04678","article-title":"NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21","volume":"441","author":"Arron","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2018.05.045_bib53","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nri1632","article-title":"NFAT proteins: key regulators of T-cell development and function","volume":"5","author":"Macian","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2018.05.045_bib54","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejmg.2015.11.010","article-title":"The acute lymphoblastic leukemia of Down Syndrome - genetics and pathogenesis","volume":"59","author":"Izraeli","year":"2016","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.canlet.2018.05.045_bib55","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jmgm.2017.01.014","article-title":"Multi-step virtual screening to develop selective DYRK1A inhibitors","volume":"72","author":"Koyama","year":"2017","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.canlet.2018.05.045_bib56","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1038\/leu.2012.84","article-title":"Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations","volume":"26","author":"Buitenkamp","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2018.05.045_bib57","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1172\/JCI66203","article-title":"Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia","volume":"123","author":"Figueroa","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2018.05.045_bib58","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s12185-012-1181-z","article-title":"Epigenetic alterations in hematopoietic malignancies","volume":"96","author":"Chung","year":"2012","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.canlet.2018.05.045_bib59","first-page":"58","article-title":"SET domain-containing protein 4 (SETD4) is a newly identified cytosolic and nuclear lysine methyltransferase involved in breast cancer cell proliferation","volume":"5","author":"Faria","year":"2013","journal-title":"J. Canc. Sci. Ther."},{"key":"10.1016\/j.canlet.2018.05.045_bib60","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4161\/epi.27585","article-title":"Epigenetic deregulation in pediatric acute lymphoblastic leukemia","volume":"9","author":"Chatterton","year":"2014","journal-title":"Epigenetics"},{"key":"10.1016\/j.canlet.2018.05.045_bib61","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13148-016-0223-4","article-title":"Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy","volume":"8","author":"Morera","year":"2016","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.canlet.2018.05.045_bib62","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.molcel.2004.08.006","article-title":"Chromosomal protein HMGN1 modulates histone H3 phosphorylation","volume":"15","author":"Lim","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2018.05.045_bib63","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1038\/sj.emboj.7600768","article-title":"Chromosomal protein HMGN1 enhances the acetylation of lysine 14 in histone H3","volume":"24","author":"Lim","year":"2005","journal-title":"EMBO J."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383518303847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383518303847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T18:32:01Z","timestamp":1563388321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383518303847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":63,"alternative-id":["S0304383518303847"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2018.05.045","relation":{},"ISSN":["0304-3835"],"issn-type":[{"type":"print","value":"0304-3835"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision medicine approaches may be the future for CRLF2 rearranged Down Syndrome Acute Lymphoblastic Leukaemia patients","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2018.05.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}